Santen Pharmaceutical Co., Ltd.

DB:SZD Stock Report

Market Cap: €3.2b

Santen Pharmaceutical Management

Management criteria checks 2/4

Santen Pharmaceutical's CEO is Takeshi Ito, appointed in Sep 2022, has a tenure of 2.25 years. total yearly compensation is ¥188.00M, comprised of 50% salary and 50% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth €786.74K. The average tenure of the management team and the board of directors is 3.4 years and 1.5 years respectively.

Key information

Takeshi Ito

Chief executive officer

JP¥188.0m

Total compensation

CEO salary percentage50.0%
CEO tenure2.3yrs
CEO ownership0.02%
Management average tenure3.4yrs
Board average tenure1.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Takeshi Ito's remuneration changed compared to Santen Pharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

JP¥26b

Jun 30 2024n/an/a

JP¥27b

Mar 31 2024JP¥188mJP¥94m

JP¥27b

Dec 31 2023n/an/a

JP¥28b

Sep 30 2023n/an/a

JP¥26b

Jun 30 2023n/an/a

-JP¥11b

Mar 31 2023JP¥103mJP¥71m

-JP¥15b

Compensation vs Market: Takeshi's total compensation ($USD1.19M) is below average for companies of similar size in the German market ($USD1.94M).

Compensation vs Earnings: Takeshi's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Takeshi Ito (65 yo)

2.3yrs

Tenure

JP¥188,000,000

Compensation

Mr. Takeshi Ito has been President and Chief Executive Officer at Santen Pharmaceutical Co., Ltd. since September 12, 2022 and serves as Representative Director since April 01, 2022. He served as Executive...

Leadership Team

NamePositionTenureCompensationOwnership
Takeshi Ito
President2.3yrsJP¥188.00m0.024%
€ 786.7k
Kazuo Koshiji
CFO & Corporate Officerno datano datano data
Rie Nakajima
COO, Corporate Officer & Director1.8yrsno data0.015%
€ 473.7k
Kaori Itagaki
General Manager of Investor Relations Groupno datano datano data
Mika Masunari
General Counsel & Chief Compliance Officer4.2yrsno datano data
Nobuko Kato
Chief Communications Officer2.9yrsno datano data
Shinichi Teramachi
Corp. Officer3.9yrsno datano data
Kenji Morishima
Corporate Officer & Head of China Product Development Department10.7yrsno datano data
Takahiro Morita
Global Head of Core Principle & Sustainability and Corporate Officer2.9yrsno datano data
Frank Binder
Corporate Officer & Head of Supply Chain Division6.9yrsno datano data
Takeshi Matsugi
Head of R&D Strategic Operationsno datano datano data
Peter Sallstig
Chief Medical Officerno datano datano data

3.4yrs

Average Tenure

Experienced Management: SZD's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Takeshi Ito
President7.4yrsJP¥188.00m0.024%
€ 786.7k
Rie Nakajima
COO, Corporate Officer & Directorless than a yearno data0.015%
€ 473.7k
Ippei Kurihara
Corporate Officerless than a yearno data0.0035%
€ 113.6k
Noboru Kotani
Independent Outside Director2.5yrsno data0.0015%
€ 47.4k
Akira Kurokawa
Chairman of the Board27.5yrsJP¥171.00m0.068%
€ 2.2m
Junichi Asatani
Outside Auditor1.5yrsno data0.00088%
€ 28.6k
Masahiko Ikaga
Independent Outside Directorless than a yearno datano data
Minoru Kikuoka
Independent Outside Directorless than a yearno datano data
Hiroshi Isaka
Standing Corporate Auditor4.5yrsno data0.00029%
€ 9.4k
Yaeko Hodaka
Outside Auditor1.5yrsno datano data
Tamie Minami
Independent Outside Director2.5yrsno datano data
Yuichiro Munakata
Independent Outside Auditorless than a yearno datano data

1.5yrs

Average Tenure

63.5yo

Average Age

Experienced Board: SZD's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 18:13
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Santen Pharmaceutical Co., Ltd. is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Philip HallBNP Paribas Securities (Asia)
Koichi MameganoBofA Global Research